Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Read More
GOOGL, NVO, Small Caps & Other Value Plays in All-Time High Market
Published: September 18, 2025 by: Schwab Network
Sentiment: Positive
Jeff McClean says A.I. valuations have ballooned to the point where the value in many have been lost.
Read More
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
Published: September 18, 2025 by: Reuters
Sentiment: Negative
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly.
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
It Is Time To Buy Novo Nordisk Hand Over Fist
Published: September 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains a Strong Buy, driven by restructuring, pipeline advancements, and robust product developments like the Wegovy pill. NVO's restructuring will cut 9,000 jobs, saving $1.27B annually by 2026, enabling reinvestment in R&D, manufacturing, and commercial execution. Recent FDA and EMA approvals for GLP-1 drugs, plus promising obesity and diabetes treatments, position NVO for significant revenue growth by 2026.
Read More
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
Published: September 17, 2025 by: Barrons
Sentiment: Positive
Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say.
Read More
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Read More
GLP-1 drugs could save millions of lives — and spark a pension crisis
Published: September 17, 2025 by: Market Watch
Sentiment: Neutral
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Read More
Novo Nordisk finds its footing again
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
After a bruising year, Novo Nordisk (NYSE:NVO) is back in favour. Berenberg has upgraded the Danish drugmaker to 'buy', setting a target price of DKK425 against a current DKK359.
Read More
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Published: September 17, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide, and helped patients lose more weight.
Read More
NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
"Reassessment" of LLY & NVO GLP-1 Projections Set New Guidance Tone
Published: September 16, 2025 by: Schwab Network
Sentiment: Positive
Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in Eli Lilly (LLY) and Novo Nordisk (NVO), anticipating significant upside following the repricing.
Read More
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
Published: September 16, 2025 by: Investopedia
Sentiment: Positive
U.S.-listed shares of Novo Nordisk (NVO) gained after the drugmaker reported positive results from a late-stage study of a weight-loss drug that works differently than traditional GLP-1 inhibitors.
Read More
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide
Published: September 16, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) shares gained on Tuesday after the company reported promising Phase 3 trial results for its experimental weight-loss drug Cagrilintide, presented at the European Association for the Study of Diabetes congress in Vienna. The REDEFINE 1 trial showed that once-weekly injections of Cagrilintide led to an average 11.8% reduction in body weight over 68 weeks, compared with 2.3% in the placebo group.
Read More
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Read More
Novo Nordisk: The Market Is Giving Us A Free Lunch
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underlying business remains strong with 18% year-over-year sales growth, proving that NVO's core momentum is still intact. Strategic catalysts like the exclusive CVS formulary win and the NovoCare direct-to-patient channel are actively working to secure future revenue and protect market share.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.
Published: September 15, 2025 by: Barrons
Sentiment: Positive
Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.
Read More
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Published: September 12, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in the coming months, said Lilly's Chief Scientific Officer Dan Skovronsky.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Novo Nordisk tells staff to return to office full-time amid CEO's revival effort
Published: September 11, 2025 by: Reuters
Sentiment: Neutral
Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid intense competition in the obesity drug market.
Read More
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Published: September 10, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroach on its market share.
Read More
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Read More
Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S's job cuts and profit outlook reset reflect a strategic pivot to margin discipline, not long-term weakness, amid evolving GLP-1 market dynamics. Despite near-term margin pressure and competitive headwinds, NVO is undervalued by ~36%, per my DCF model, and offers an attractive entry point, especially under $52/share. GLP-1 market shifts—coverage expansion, adherence gains, and next-gen drugs—should expand Novo's addressable market and support long-term growth beyond 2025.
Read More
Novo Nordisk to cut 9,000 jobs
Published: September 10, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Michael Santoli and Melissa Lee discuss pharmaceutical company Novo Nordisk cutting jobs.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406